{"id":"NCT00050960","sponsor":"Eisai Inc.","briefTitle":"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer","officialTitle":"Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Na√Øve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-05","primaryCompletion":"2004-07","completion":"2005-03","firstPosted":"2003-01-03","resultsPosted":"2010-08-24","lastUpdate":"2012-07-13"},"enrollment":612,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"bexarotene with carboplatin and paclitaxel","otherNames":[]},{"type":"DRUG","name":"carboplatin and paclitaxel","otherNames":[]}],"arms":[{"label":"bexarotene with carboplatin and paclitaxel","type":"EXPERIMENTAL"},{"label":"carboplatin and paclitaxel","type":"EXPERIMENTAL"}],"summary":"This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From date of randomization to date of death","effectByArm":[{"arm":"Bexarotene With Carboplatin and Paclitaxel","deltaMin":8.5,"sd":null},{"arm":"Carboplatin and Paclitaxel","deltaMin":9.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":154,"countries":["United States","Austria","Canada","France","Germany","Spain"]},"refs":{"pmids":[],"seeAlso":["http://www.Ligand.com"]},"adverseEventsSummary":{"seriousAny":{"events":256,"n":293},"commonTop":["Alopecia","Fatigue","Nausea","Anemia","Neutropenia"]}}